ARCA biopharma Stock Forecast, Price & News

-0.05 (-1.37 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume210,560 shs
Average Volume670,388 shs
Market Capitalization$52.02 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ABIO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

About ARCA biopharma

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.90 out of 5 stars

Medical Sector

1177th out of 2,100 stocks

Diagnostic Substances Industry

22nd out of 35 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ARCA biopharma (NASDAQ:ABIO) Frequently Asked Questions

What stocks does MarketBeat like better than ARCA biopharma?

Wall Street analysts have given ARCA biopharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ARCA biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ARCA biopharma?

ARCA biopharma saw a decrease in short interest in May. As of May 28th, there was short interest totaling 323,400 shares, a decrease of 31.6% from the May 13th total of 472,700 shares. Based on an average daily trading volume, of 342,500 shares, the days-to-cover ratio is presently 0.9 days. Currently, 2.3% of the shares of the company are short sold.
View ARCA biopharma's Short Interest

When is ARCA biopharma's next earnings date?

ARCA biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for ARCA biopharma

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) issued its quarterly earnings results on Tuesday, May, 11th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks' consensus estimate of ($1.87) by $1.54.
View ARCA biopharma's earnings history

How has ARCA biopharma's stock been impacted by COVID-19?

ARCA biopharma's stock was trading at $3.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABIO stock has increased by 7.4% and is now trading at $3.61.
View which stocks have been most impacted by COVID-19

Who are ARCA biopharma's key executives?

ARCA biopharma's management team includes the following people:
  • Dr. Michael R. Bristow, Co-Founder, Pres, CEO & Director (Age 76, Pay $441.61k)
  • Mr. Thomas A. Keuer, Chief Operating Officer (Age 62, Pay $402.61k)
  • Mr. Christopher D. Ozeroff, Sr. VP, Gen. Counsel & Sec. (Age 62, Pay $376.38k)
  • Mr. C. Jeffrey Dekker, Chief Financial Officer (Age 56)
  • Dr. Debra Marshall FACC, M.D., Chief Medical Officer

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma CEO Michael R. Bristow on Michael R. Bristow has an approval rating of 100% among ARCA biopharma's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ARCA biopharma's key competitors?

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

Who are ARCA biopharma's major shareholders?

ARCA biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include GSA Capital Partners LLP (0.65%), Geode Capital Management LLC (0.55%), Morgan Stanley (0.28%), PDT Partners LLC (0.12%) and Virtu Financial LLC (0.12%).
View institutional ownership trends for ARCA biopharma

Which major investors are selling ARCA biopharma stock?

ABIO stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for ARCA biopharma
or view top insider-selling stocks.

Which major investors are buying ARCA biopharma stock?

ABIO stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Geode Capital Management LLC, Morgan Stanley, and PDT Partners LLC.
View insider buying and selling activity for ARCA biopharma
or or view top insider-buying stocks.

How do I buy shares of ARCA biopharma?

Shares of ABIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $3.61.

How much money does ARCA biopharma make?

ARCA biopharma has a market capitalization of $52.02 million.

How many employees does ARCA biopharma have?

ARCA biopharma employs 11 workers across the globe.

What is ARCA biopharma's official website?

The official website for ARCA biopharma is

Where are ARCA biopharma's headquarters?

ARCA biopharma is headquartered at 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The biopharmaceutical company can be reached via phone at 720-940-2200 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.